Back to Search
Start Over
Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer
- Source :
- Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
- Publication Year :
- 2024
- Publisher :
- Nature Portfolio, 2024.
-
Abstract
- Abstract Immune checkpoint inhibitors (ICIs) have become an important cornerstone of many tumour treatments. However, the toxicity profile of immune-chemotherapy combination treatment approaches among older adult cancer patients is still unclear. Patients with any cancer who received camrelizumab-based immunotherapy were eligible for inclusion. The primary endpoints were adverse events (AEs) and immune-related adverse events (irAEs), which were defined based on Naranjo's algorithm. Patients were stratified by age (≥ 70 years and
- Subjects :
- Immune checkpoint inhibitors
Ageing
Immunotherapy
Cancer
Toxicity
Medicine
Science
Subjects
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 14
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Scientific Reports
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.ba3ea96789cf4016b93b9bca4d491e90
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41598-024-69944-w